Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis

7Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. Method: We retrospectively identified pT1-3N0M0 esophageal carcinoma patients between 2000 and 2016 from the Surveillance, Epidemiology, and End Results database. Patients with upfront esophagectomy were categorized as having received surgery alone (SA) and surgical resection followed by adjuvant radiotherapy (SA + RT). Propensity score matching, univariate and multivariate analysis were performed to compare overall survival (OS) and cause-specific survival (CSS). Results: A total of 2862 patients were identified, of whom 274 received SA + RT and 2588 received SA. The median follow-up was 60.4 months (95%CI, 58.7–62.1 months). The five-year OS and CSS were better for SA group compared with SA + RT group (P < 0.001, respectively). Furthermore, after matching, the OS and CSS were still significantly better for SA patients. For T subgroup analysis, postoperative radiotherapy was an independent prognostic factor only for pT1 patients with worse OS, without survival differences for pT2 and pT3 patients. However, after multivariate cox analysis, postoperative radiotherapy can provide significantly better OS for pT3 patients with tumor length ≥5 cm (P = 0.03; 95%CI, 0.29–0.94). Conclusions: Among pT1-3N0M0 esophageal carcinoma patients, postoperative radiotherapy can provide significantly better OS for pT3 patients with tumor length ≥5 cm. However, there are no survival benefits for pT1-2 patients after SA + RT procedure. This finding may have significant implications on the use of adjuvant radiation in patients with pN0 disease.

References Powered by Scopus

Cancer Statistics, 2017

14509Citations
N/AReaders
Get full text

Preoperative chemoradiotherapy for esophageal or junctional cancer

4545Citations
N/AReaders
Get full text

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial

2004Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Postoperative radiotherapy for thoracic esophageal carcinoma with upfront r0 esophagectomy

5Citations
N/AReaders
Get full text

Survival risk prediction model for patients with pT<inf>1–3</inf> N<inf>0</inf>M<inf>0</inf> esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes

2Citations
N/AReaders
Get full text

Development and validation of a prognostic nomogram for esophageal cancer patients based on SEER Asian population

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gao, H. J., Shang, X. B., Gong, L., Zhang, H. D., Ren, P., Shi, G. D., … Yu, Z. T. (2020). Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis. Thoracic Cancer, 11(2), 243–252. https://doi.org/10.1111/1759-7714.13235

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

80%

Researcher 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

75%

Agricultural and Biological Sciences 1

25%

Save time finding and organizing research with Mendeley

Sign up for free